[{"orgOrder":0,"company":"Phoenix Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Journal Article Reviews Phoenix's Oleandrin\u2019s Antiviral Activity Against \u2018Enveloped\u2019 Viruses, Including Sars-Cov2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"Phoenix Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Study Presents Evidence of Effectiveness and Safety Of Oleandrin and Phoenix Biotechnology\u2019s PBI-06150 Against SARS-CoV-2","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals for Oleandrin
The in vitro study, using Vero cells, found that “prophylactic oleandrin (as either the pure compound or as the active principal ingredient in PBI-06150) administration at concentrations as low as 0.05 μg/ml exhibited potent antiviral activity against SARS-CoV-2.
Published reports from in vitro cell culture studies have shown that oleandrin and extracts containing this molecule are effective against HIV, the Ebola virus as well as HTLV-1 and other viruses that are harmful to human health and well-being.